<DOC>
	<DOCNO>NCT00400582</DOCNO>
	<brief_summary>The purpose study evaluate impact genetic variation response candesartan patient heart failure already treat ACE inhibitor .</brief_summary>
	<brief_title>A Pharmacogenomic Study Candesartan Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Principal 1 . Male female &gt; = 18 year old . 2 . Symptomatic CHF correspond NYHA class IIIV symptoms least 4 week prior randomization . 3 . LVEF &lt; = 40 % 4 . Treatment optimal stable dose ACE inhibitor least 4 week prior enrolment study . Principal 1 . Treatment ARB within 8 week prior randomization . 2 . Known hypersensitivity ARBs ACE inhibitor . 3 . Creatinine clearance &lt; 30 ml/min serum creatinine &gt; 221 4 . Current serum potassium &gt; = 5.0 mmol/L history mark ACE inhibitor ARB induce hyperkalemia . 5 . Known bilateral renal artery stenosis . 6 . Current symptomatic hypotension and/or systolic B.P . &lt; 90 mmHg . 7 . Decompensated heart failure describe hospitalization I.V . administration medication emergency room heart failure clinic within 4 week 8 . Stroke , acute coronary syndrome , PCI within last 4 week randomization . 9 . Connective tissue disease chronic inflammatory condition 10 . Acute inflammatory process infection gout attack last 2 week . 11 . Pregnant lactate woman woman childbearing potential protected pregnancy accept method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Gene polymorphism</keyword>
	<keyword>Candesartan</keyword>
	<keyword>ACE inhibitor</keyword>
	<keyword>BNP</keyword>
	<keyword>Pharmacogenomics</keyword>
</DOC>